Drugs / DFL24498
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07503886 | May 2026 → Jan 2027 expected | dry eye syndrome | Dompé Farmaceutici S.p.A | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07395232 | Dec 2025 → Mar 2027 expected | atopic keratoconjunctivitis | Dompé Farmaceutici S.p.A | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFL24498 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07503886 ↗ |
| Route | Other | “DFL24498 will be instilled in each eye for 12 Weeks.” NCT07395232 ↗ |